Mimedx (MDXG) Amortization - Intangibles (2012 - 2026)
Mimedx (MDXG) posted Amortization - Intangibles of $291000.0 for Q2 2026, down 3.32% sequentially from $301000.0 in Q1 2026, and up 191.0% YoY from $100000.0 in Q2 2025.
Mimedx (MDXG) Amortization - Intangibles (2012 - 2026) Analysis & Trends
Mimedx has reported Amortization - Intangibles for 15 years, with the latest figure at $291000.0 in Q2 2026.
- Quarterly Amortization - Intangibles rose 191.0% year-over-year to $291000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $833000.0 (up 42.64% YoY) and the FY2025 annual result came in at $439000.0, down 42.61% from the prior year.
- Amortization - Intangibles eased to $291000.0 in Q2 2026 per MDXG's latest filing, from $301000.0 in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $301000.0 in Q1 2026 and troughed at $99000.0 in Q1 2025.
- A 5-year average of $181166.7 and a median of $189500.0 in 2023 frame the typical range for Amortization - Intangibles.
- The sharpest annual moves came in 2025 and 2026: Amortization - Intangibles tumbled 47.62% in 2025, then soared 204.04% in 2026.
- Over 5 years, Amortization - Intangibles stood at $182000.0 in 2022, then climbed by 5.49% to $192000.0 in 2023, then gained by 0.52% to $193000.0 in 2024, then sank by 33.16% to $129000.0 in 2025, then jumped by 125.58% to $291000.0 in 2026.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $291000.0, $301000.0, and $129000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 291,000.00 |
| Mar 31, 2026 | 301,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2024 | 193,000.00 |
| Sep 30, 2024 | 192,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | 192,000.00 |
| Sep 30, 2023 | 190,000.00 |
| Jun 30, 2023 | 191,000.00 |
| Mar 31, 2023 | 190,000.00 |
| Dec 31, 2022 | 182,000.00 |
| Sep 30, 2022 | 175,000.00 |
| Jun 30, 2022 | 173,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 173,000.00 |
| Sep 30, 2021 | 193,000.00 |